论文部分内容阅读
目的观察和评价益肺通络方联合西药化疗方案治疗耐多药肺结核的疗效。方法将225例患者随机分为观察组124例采用益肺通络方联合西药化疗方案治疗,对照组101例采用单纯西药化疗方案治疗,观察两组治疗第3、6、9、12、15、18、21、24月的临床疗效及安全性。结果疗程结束时,观察组痰菌阴转率、中医症候学指标及免疫功能改善均优于对照组,其中痰结核菌转阴率(3、6月)、中医症候学指标(3、6、9月)及免疫学指标CD4比值(6月)观察组与对照组比较差异有统计学意义(P<0.05)。结论益肺通络方联合西药化疗方案治疗耐多药肺结核可促进痰菌阴转、症状改善及提高患者免疫功能,临床有效且安全,为耐多药肺结核患者的治疗选择了新路径,具有临床推广应用前景。
Objective To observe and evaluate the efficacy of Yifei Tongluo Recipe plus western medicine chemotherapy in the treatment of multidrug-resistant pulmonary tuberculosis. Methods A total of 225 patients were randomly divided into observation group (124 cases) treated with Yifei Tongluo decoction combined with western medicine chemotherapy and control group (101 cases) treated with western medicine chemotherapy alone. Two groups were treated with 3, 6, 9, 12, 18, 21, 24 months of clinical efficacy and safety. Results At the end of the course of treatment, sputum negative conversion rate, TCM symptom index and immune function improvement in the observation group were better than those in the control group. The sputum negative rate of sputum TB (3, 6 months), TCM symptom index (3, 6, 9 months) and CD4 ratio of immunological indicators (June), the difference between the observation group and the control group was statistically significant (P <0.05). Conclusion Yifei Tongluo Decoction combined with western medicine chemotherapy for multidrug-resistant pulmonary tuberculosis can promote sputum negative conversion, improve symptoms and improve immune function in patients. It is clinically effective and safe, and provides a new route for the treatment of multi-drug resistant pulmonary tuberculosis. Promote the application prospects.